-
Novartis reveals promising interim Phase 3 data for gene therapy Zolgensma in spinal muscular atrophy
pharmafile
April 23, 2019
Novartis has revealed new interim data from its Phase 3 trial investigating the efficacy of its gene therapy Zolgensma (onasemnogene abeparvovec-xioi; AVXS-101) in the treatment...
-
New data reinforce effectiveness of Novartis’ Zolgensma for SMA
pharmatimes
April 21, 2019
New AveXis data has reinforced the effectiveness of Novartis’ spinal muscular atrophy (SMA) Type I drug, Zolgensma (onasemnogene abeparvovec-xioi).
-
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1
drugs
April 18, 2019
AveXis Data Reinforce Effectiveness of Zolgensma in Treating Spinal Muscular Atrophy (SMA) Type 1.
-
New data reinforce effectiveness of Novartis’ Zolgensma for SMA
pharmatimes
April 18, 2019
The Phase III STR1VE data show prolonged event-free survival, early and rapid increases in The Children's Hospital of ……
-
Late-stage pipeline drugs could compete with only treatment for SMA
europeanpharmaceuticalreview
April 10, 2019
A number of drugs currently in their late stages in the development process could see competition for nusinersen, the only current SMA treatment, rise…
-
China National Medical Products Association Approves SPINRAZA
americanpharmaceuticalreview
March 01, 2019
Biogen announced that SPINRAZA has been approved by the China National Medical Products Association for the treatment of 5q spinal muscular atrophy,expanding the company’s presence in China.
-
Roche gets PRIME designation for SMA drug in Europe
pharmaceutical-technology
December 20, 2018
Roche has secured PRIME designation from the European Medicines Agency (EMA) for its risdiplam (RG7916) medicine to treat spinal muscular atrophy (SMA).
-
Novartis says $4m price is reasonable for SMA gene therapy
pharmaphorum
December 14, 2018
Novartis says it thinks its one-off gene therapy for spinal muscular atrophy (SMA) could deliver value for money even if its price was set upwards of $4 million – which would set a record for a pharmaceutical product.
-
FDA accepts Novartis application for Zolgensma to treat SMA
pharmaceutical-technology
December 04, 2018
The US Food and Drug Administration (FDA) has agreed to review a biologics licence application (BLA) by Novartis seeking approval for Zolgensma (AVXS-101) for treating spinal muscular atrophy (SMA) Type 1......
-
Novartis snaps up AveXis in $8.7bn deal
pharmatimes
July 17, 2018
Novartis is buying US gene therapy group AveXis in a deal valued at $8.7 billion.